Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 08 Oct
    2018

    Scottish Medicines Consortium approves the use of Alkindi® as first-line treatment for paediatric adrenal insufficiency

    Scottish Medicines Consortium (SMC) has today approved the routine use of Alkindi® (hydrocortisone granules in capsules for opening) as the first-line treatment of young children with adrenal insufficiency aged from birth to less than six years of age 

    Read More

  • 08 Oct
    2018

    Headline data for Chronocort® European Phase III clinical trial

    Headline data from the Chronocort® pivotal Phase III clinical trial in Europe for adults with congenital adrenal hyperplasia (CAH).

    Read More

  • 05 Oct
    2018

    First patients enrolled in US Chronocort® pivotal Phase III clinical trial for congenital adrenal hyperplasia

    First two patients have been enrolled into the pivotal Phase III clinical trial (“RESTORE”) in the US for adults with congenital adrenal hyperplasia (CAH).

    Read More